Waiting
Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove

Cancer Research

Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion

Published: July 6, 2022 doi: 10.3791/63281
* These authors contributed equally

Summary

This protocol describes the methods of subculture and cryopreservation of esophageal adenocarcinoma organoids with and without single cell digestion to enable researchers to choose appropriate strategies based on their experimental design.

Abstract

The lack of suitable translational research models reflecting primary disease to explore tumorigenesis and therapeutic strategies is a major obstacle in esophageal adenocarcinoma (EAC). Patient-derived organoids (PDOs) have recently emerged as a remarkable preclinical model in a variety of cancers. However, there are still limited protocols available for developing EAC PDOs. Once the PDOs are established, the propagation and cryopreservation are essential for further downstream analyses. Here, two different methods have been standardized for EAC PDOs subculture and cryopreservation, i.e., with and without single cell digestion. Both methods can reliably obtain appropriate cell viability and are applicable for a diverse experimental setup. The current study demonstrated that subculturing EAC PDOs with single cell digestion is suitable for most experiments requiring cell number control, uniform density, and a hollow structure that facilitates size tracking. However, the single cell-based method shows slower growth in culture as well as after re-cultivation from frozen stocks. Besides, subculturing with single cell digestion is characterized by forming hollow structures with a hollow core. In contrast, processing EAC PDOs without single cell digestion is favorable for cryopreservation, expansion, and histological characterization. In this protocol, the advantages and disadvantages of subculturing and cryopreservation of EAC PDOs with and without single cell digestion are described to enable researchers to choose an appropriate method to process and investigate their organoids.

Introduction

Esophageal cancer (EC) is the tenth most common and the sixth leading cause of death from cancer worldwide1. Esophageal adenocarcinoma (EAC) is one of the major histologic subtypes of EC and mainly occurs in western countries2. In the recent decade, the EAC incidence has significantly increased in many developed countries, including Germany3. Due to the aggressiveness of cancer and the lack of symptoms during the early stage of tumor development, the overall prognosis in EAC patients is poor, showing a 5-year survival rate of about 20%2,4,5.

Since the late twentieth century, several models have been established for the biomedical research of EAC. The classic human EAC cell lines that were established in the 1990s6, extend our knowledge of EAC tumor biology, tumor genetics as well as anti-tumor strategies, and are commonly used in EAC research. Besides, some research groups have successfully developed animal models of EAC or Barrett's esophagus by exposing the animals to known risk factors such as gastroesophageal reflux through surgical or inflammatory approaches7,8,9. In addition, patient-derived xenograft (PDX) models that engraft EAC primary cancer tissues subcutaneously or orthotopically into immunodeficient mice, were developed to simulate human EAC tumor biological behavior and tumor environment10,11,12. However, despite these models improving clinical applications and our understanding of molecular mechanisms behind EAC tumorigenesis and progression, there is still a major challenge to extrapolate results from these research models to humans.

Patient-derived tumor organoids (PDOs) are grown in a 3D culture system that mimics human development and organ regeneration in vitro. Generated from patients' primary tissue, PDOs recapitulate the molecular and phenotypic characteristics of the human tumor and have shown promising applications in drug development and personalized cancer treatment13,14. By comparing ten cases of EAC PDOs with their paired tumor tissue, EAC PDOs are reported to share similar histopathological features and genomic landscape with the primary tumor, retain intra-tumor heterogeneity and facilitate efficient drug screening in vitro15. EAC PDOs were also used in studying the interaction of EAC tumor cells with patient-derived cancer-associated fibroblasts (CAFs), indicating a powerful application in the field of tumor microenvironment research16. Unfortunately, there have been limited protocols available for developing and propagating EAC PDOs. Here, two different methods are described for subculturing and preserving EAC PDOs in detail: with and without single cell digestion. The standardized methods for maintenance of EAC PDOs and their applications can support researchers to choose appropriate methods for different purposes in their EAC PDO research.

Subscription Required. Please recommend JoVE to your librarian.

Protocol

An established and well-growing PDO culture represents the basis for a successful subculture and cryopreservation described in this protocol. Here, EAC PDOs were generated from EAC patients' primary tumor tissue using the protocol described by Karakasheva T. A. et al17. EAC tissues were collected from biobank under the approval of BioMaSOTA (approved by the Ethics Committee of the University of Cologne, ID: 13-091).

NOTE: EAC PDOs have been cultured in a humidified incubator at 37 °C and 5% CO2 using a PDO culture medium (Table 1). In the following steps, two methods of the subculture are described in detail. A 12-well plate is recommended for subculturing the PDOs with a seeding density of three extracellular matrix (ECM) gel domes per well, as it allows flexible use of each well and appropriate quantity of PDOs for different purposes. An aseptic technique is compulsory while handling the PDOs.

1. Preparations in advance

  1. Pre-warm a 12-well plate by placing it into a 37 °C CO2 incubator overnight before subculture to ensure complete warming of the plate. If available, use empty wells from a plate with the current PDO culture.
    NOTE: Continuous storage of 1-2 fresh plates at 37 °C is recommended for flexible subculture planning.
  2. Pre-cool 1,000 µL and 200 µL tips with a wide orifice at -20 °C (continuous storage recommended). Pre-cool centrifuge at 4 °C.
  3. Set up the temperature of the rotating incubator to 37 °C (if single cell digestion is performed).
  4. Incubate an appropriate volume of ECM gel for 1 h on ice to liquefy. Place cell recovery solution on ice.

2. Harvesting organoids

  1. Remove the plate with growing PDOs from the CO2incubator.
  2. Aspirate old medium using a vacuum pump.
    NOTE: Avoid touching the domes.
  3. Add an appropriate volume of ice-cold cell recovery solution (500 µL/dome) into the well.
  4. Disintegrate the ECM gel by pipetting up and down several times to fragment ECM gel domes into small pieces using 1,000 µL tips with a wide orifice.
  5. Combine the mixture of PDO, ECM gel and cell recovery solution from a maximum of two wells (six domes) and transfer it into a 5 mL low bind tube (use a second tube in case more wells are used for subculture).
    NOTE: Optionally, if ECM gel was not dissolved completely, add an additional 1.5 mL of cell recovery solution to the mixture of PDO, ECM gel, and cell recovery solution.
  6. Incubate the tube containing the mixture in step 2.5 on ice for 20 min, mix every 5 min by inverting the tube five times to ensure the liquefaction of the ECM gel.
  7. Centrifuge at 500 x g for 4 min at 4° C.
  8. If there is a visible and stable pellet after centrifugation, proceed with step 2.10. Otherwise, continue with step 2.9.
  9. If there is no visible pellet and the PDOs still seem to be stuck in a gel phase, carefully remove the supernatant with a vacuum pump until the phase containing ECM gel-PDO-Solution is reached and add 3 mL of ice-cold cell recovery solution.
    1. Invert the tube a few times and incubate on ice for another 10 min. Mix by inverting the tube from time to time.
    2. Centrifuge at 500 x g for 4 min at 4 °C and continue with step 2.10.
  10. Discard the supernatant carefully using a vacuum pump or a 1,000 µL pipette. Try to remove the supernatant as much as possible.
    NOTE: Due to the low bind surface of the tube, the pellet will not be as stable as usual.
  11. Store the PDO pellet on ice and proceed with step 3 (without digestion) or step 4 (with single cell digestion) depending on the different purposes.

3. Subculturing without digestion

NOTE: This method aims to increase the PDOs' size and density. The larger size and higher density facilitate the embedding process, histological characterization, and PDO expansion. Depending on the PDO split ratios (based on the density of PDOs, a ratio between 1:3 and 1:6 is recommended), resuspend the pellet from step 2.8 in an appropriate volume of liquid ECM gel.

  1. Remove pre-cooled 200 µL and 1,000 µL tips with a wide orifice from the -20 °C freezer and place them onto a clean bench.
  2. Resuspend the pellet from step 2.11 in ECM gel using pre-cooled 1,000 µL tips. Mix by pipetting up and down about 10 times to make sure PDOs are not clumping and are evenly distributed in the ECM gel.
    NOTE: Use 50 µL ECM gel/dome. Always calculate for one dome more than required (e.g., for nine domes (i.e., three wells), resuspend the pellet in 500 µL of liquid ECM gel (450 + 50 µL extra). Try to avoid producing bubbles during resuspension!
  3. Remove the pre-warmed 12-well plate from the incubator right before seeding the domes.
  4. Seed domes containing 50 µL ECM gel into the warm plate (three domes/well). Avoid pipetting bubbles into the ECM gel domes.
  5. Put the plate back into the 37 °C and 5% CO2incubator and incubate for 20-30 min to solidify the ECM gel.
  6. Add pre-warmed PDO medium (Table 1) carefully without disturbing the domes.
  7. Culture the PDOs for 7-14 days until the required density and morphology occur.

4. Subculturing with single cell digestion

NOTE: The following steps aim to increase the number of PDOs per dome. The single cell digestion facilitates cell number control and PDO expansion.

  1. Prepare digestion medium by mixing 2 mL of 0.25% Trypsin-EDTA and 20 µL DNase I (for digestion of three domes).
  2. Resuspend the pellet from step 2.11 with an appropriate volume of pre-warmed 0.25% Trypsin-EDTA + DNase I and mix it about 10 times by pipetting up and down using a 1,000 µL pipette (use normal 1,000 µL tips).
  3. Incubate for 10 min at 37 °C in a rotating incubator with a rotation speed of a minimum 28 rpm.
  4. Prepare a 15 mL tube containing 6 mL of Soybean Trypsin Inhibitor (STI, Table 2) solution (per 2 mL of 0.25% Trypsin-EDTA).
  5. After digestion, mix the digested PDOs thoroughly a few times with a 1,000 µL pipette to disrupt the PDOs.
  6. Transfer the digested PDOs to the 15 mL tube containing STI solution to stop the digestion process.
  7. Centrifuge at 500 x g for 4 min at 4 °C. Discard the supernatant carefully using a vacuum pump or a 1,000 µL pipette. Resuspend the pellet in 1 mL of basal medium (Table 3).
  8. Determine cell concentration and viability using an automated cell counter or a Hemocytometer.
  9. Seed digested PDO into a 12-well plate with 2 x 104 cells per dome.
    1. Calculate the cell number according to the domes planned for seeding and transfer them to a fresh 1.5 mL low bind tube.
      NOTE: Calculate for one dome more (+ 2 x 104 cells extra). For example, for seeding three domes into one well, take 8 x 104 (2 x 104* 3 + 2 x 104 extra) cells.
    2. Centrifuge at 500 x g for 4 min at 4 °C.
    3. In case there is no visible pellet, remember the orientation of the tube inside the centrifuge to know where the pellet is located.
    4. Carefully discard the supernatant using a 1,000 µL pipette. Remove the supernatant as much as possible without disturbing the pellet.
    5. Add appropriate volume of ECM gel to the pellet using a 1,000 µL pipette with pre-cooled 1,000 µL wide orifice tip (50 µL/dome + 50 µL extra).
    6. Follow steps 3.3-3.7.

5. Cryopreservation of the digested and undigested PDOs

NOTE: Single cell digested and undigested PDOs are suitable for the preparation of frozen backup stocks. Note that re-cultivated PDOs from the single cell frozen stocks require a longer time to recover and to reach a certain size.

  1. Cryopreservation of the undigested PDOs.
    1. Start cryopreservation process with the pellet from step 2.8. Use 500 µL of cold freezing medium to resuspend the pellet and transfer it to a cryogenic vial.
      NOTE: Store two domes per vial.
    2. Freeze PDOs overnight in a -80 °C freezer using an appropriate cell freezing container.
  2. Cryopreservation of the single cell digested PDOs
    1. After harvesting and digesting PDOs, start cryopreservation from step 4.8.
    2. For storing one cryogenic vial, transfer 4-5 x 105 cells into a fresh 1.5 mL low bind tube.
      NOTE: Store three domes/vial.
    3. Centrifuge at 500 x g for 4 min at 4 °C. Discard the supernatant carefully using a 1,000 µL pipette. Remove the supernatant as much as possible without disturbing the pellet.
    4. Resuspend the pellet in an appropriate volume of freezing medium (500 µL/vial) and transfer it to a cryogenic vial.
    5. Freeze PDOs overnight in a -80 °C freezer using an appropriate cell freezing container and transfer them into a -150 °C freezer or liquid nitrogen for long-term storage.

Subscription Required. Please recommend JoVE to your librarian.

Representative Results

This protocol presents the procedures including subculture and cryopreservation of EAC PDOs with and without single cell digestion.

Figure 1 shows representative phase-contrast pictures of the two different subculture strategies. EAC PDOs reached appropriate density for subculturing (Figure 1, left). Subculturing without single cell digestion takes less time to reach comparable density and mainly leads to compact structures (Figure 1, top row). In contrast, the single cell digested PDOs show hollow structures with a hollow core (Figure 1, bottom row). Figure 2 shows the Hematoxylin-Eosin (H&E) staining and immunohistochemistry (IHC) staining of paraffin-embedded EAC PDOs with compact and hollow structures. The pan-cytokeratin (Pan-CK) enables the identification of epithelial tumor cells18. The cytokeratin 7 (CK7) highlights the glandular differentiated tumor cells19. The compact structure (top row) predominantly exists in the undigested culture, while the hollow structure (bottom row) is dominant in the culture that underwent single cell digestion.

Figure 3 shows the immunofluorescence (IHC) staining of paired EAC tissue and PDOs with compact structure and hollow structure. The Ki67 highlights the cell populations with higher cellular proliferation20. The Ki67 (red) and Pan-CK (green) were similarly distributed among EAC primary tissue, EAC PDO compact structure, and EAC PDO hollow structure. Figure 4 shows the morphological characteristics of EAC PDOs on the first day of recovery from frozen stock with single cell-based cryopreservation (left) and undigested PDO-based cryopreservation (right).

Figure 5 summarizes a flow chart of the subculture process of EAC PDOs with and without single cell digestion. Briefly, a well growing EAC PDO is ready to be passaged. EAC PDOs were harvested and pelleted. For single cell digestion, PDOs were enzymatically digested for 5-10 min to get single cells, which were likely to grow into hollow structures that facilitate experiments requiring cell number control, uniform density, and size tracking. For undigested subculture, PDOs were split to gain more growing space without enzymatically disrupting, which were likely to grow into compact structures that facilitate histological analyses, quick expansion, and faster recovery from cryopreservation.

Figure 1
Figure 1: Morphological characteristics of EAC PDOs subculture with and without single cell digestion under a phase-contrast microscope. EAC PDOs grow to a certain density prior to subculture (left). Upon subculturing EAC PDOs without single cell digestion, PDOs gradually grow from hollow structures to compact structures (right, top row), whereas PDOs grown from single cells show predominantly hollow structures (right, bottom row). Pictures were taken with inverted light microscope using a 5x objective. Scale bar: 100 µm. Please click here to view a larger version of this figure.

Figure 2
Figure 2: Histological characteristics of EAC PDOs' compact structure and hollow structure. The H&E staining (left), Pan-CK staining (middle), and CK7 staining (right) of the compact structure (top row) and hollow structure (bottom row). Pictures were taken with inverted light microscope using a 20x objective. Scale bar: 50 µm. Please click here to view a larger version of this figure.

Figure 3
Figure 3: Immunohistochemistry staining of paired EAC tissue and PDOs. The immunofluorescence (IF) staining of paired EAC tissue (top row), compact structure (middle row) and hollow structure (bottom row) with Pan-CK (green), Ki67 (red), and DAPI (blue). Pictures were taken with inverted automated fluorescence microscope using a 20x objective. Scale bar: 50 µm. Please click here to view a larger version of this figure.

Figure 4
Figure 4: Morphological characteristics of EAC PDOs on the first day of recovery from frozen stock. Phase-contrast pictures of recultivation from single cell-based cryopreservation (left) and undigested PDO-based cryopreservation (right) on the first day of recovery. Pictures were taken with inverted light microscope using a 5x objective. Scale bar: 100 µm. Please click here to view a larger version of this figure.

Figure 5
Figure 5: The flow chart of the subculture process of EAC PDOs with and without single cell digestion. Please click here to view a larger version of this figure.

Stock Final Concentration 50 mL
Basal medium (see Table 3) 24 mL
Wnt-3A conditioned medium 12 mL
R-Spondin1 conditioned medium from Cultrex R-Spondin Cells 12 mL
N-2 100x 1x 500 μL
B-27 50x 1x 1 mL
N-Acetylcysteine 0.5 M 1 mM 100 μL
CHIR-99021 5 mM 0.5 µM 5 μL
Recombinant human epidermal growth factor (EGF) 100 µg/mL 250 ng/mL 125 μL
A83-01 25 mM 0.5 µM 1 μL
SB202190 10 mM 1 µM 5 μL
Gastrin 100 µM 0.1 µM 50 μL
Nicotinamide 1 M 20 µM 1 mL
Gentamicin 50 mg/mL 10 µM 5 μL
Penicillin/Streptomycin 100x 1x 500 μL
Amphotericin B 250 µg/mL 0.60% 300 μL
Add freshly into well:
Noggin 100 µg/mL 50 μL
Y-27632 10.5 mM 50 μL
Add when establishing new PDOs from primary tissue or recovering from frozen stocks
FGF-10a 100 µg/mL 100 ng/mL 50 μL

Table 1: Preparation of EAC PDO culture medium.

Soybean Trypsin Inhibitor (STI) 12.5 mg
Adjust to 50 mL with DPBS
Filter through 0.2 µm sterile filter

Table 2: Preparation of Soybean Trypsin Inhibitor (STI) solution.

Reagent Volume Final concentration
Advanced DMEM/F-12 48.2 mL
HEPES (1 M) 500 µL 10 mM
L-Glutamine (100X) 500 µL 1X
Penicillin-Streptomycin (100X) 500 µL 1X
Amphotericin B 300 µL 0.60%
Gentamicin (50 mg/mL) 5 µL 5 µg/mL

Table 3: Preparation of basal medium.

Single cell digestion
Pros Cons
Cell number control Fragile during embedding
Viability check Longer time needed between passages
Applicable for e.g., Drug Screening, Flow Cytometry Longer recovery time from frozen stocks
Without single cell digestion
Pros Cons
Morphology is beneficial for histological analyses Expansion of PDOs more in size than in number
Higher stability in embedding process Not applicable for analyses where single cell suspension is mandatory
Quick recovery from frozen stocks Lack of cell number control and size tracking

Table 4: Pros and cons for subculturing EAC PDOs with and without single cell digestion.

Subscription Required. Please recommend JoVE to your librarian.

Discussion

In this protocol, two different subculture and cryopreservation methods of EAC PDOs are described, i.e, with and without single cell digestion. Several studies recommended passaging EAC PDOs with single cell digestion15,17, which is beneficial to most experiments that require cell number control, uniform density, and a hollow structure that facilitates size tracking. However, the single cell-based method is characterized by slower growth after recultivation from frozen stocks and less compact morphology during the culture period. Experience indicates 2-3 weeks for single cell-based recultivation to reach applicable density for the subculture process. In contrast, frozen EAC PDOs without single cell digestion can reach the same size in a shorter period (about 1 week) after recultivation. One reason could be the extra stress from the trypsin digestion for a relatively long time (10 min). Therefore, it is recommended to preserve undigested EAC PDOs in a ratio of 1:1.5 (freezing two domes of undigested EAC PDOs and seeding back into three domes for the recultivation). In addition, using undigested EAC PDOs is recommended for quick expansion and histological characterization by IHC or IF staining due to the compact structure. The pros and cons of the two subculture methods are summarized in Table 4.

Several critical steps require attention in this protocol. Firstly, the plates for PDO culture need to be pre-warmed overnight in a 37 °C incubator to ensure the solidifying process of freshly seeded ECM gel domes. It is recommended to use a hot plate for keeping the plate at 37 °C while dealing with extended seeding duration. Secondly, low bind tubes are required during the subculture process to avoid significant PDO loss. To prevent ECM gel loss, tips with a wide bore opening can be pre-cooled in the -20 °C freezer before use. Here, the wide opening of the tips avoids the damage of PDO structures during the harvesting step. Next, it is recommended to incubate PDOs for 20 min on ice before the first centrifugation step, to ensure complete liquefying of the ECM gel. Note that the centrifuge needs to be set at 4 °C during centrifugation steps to keep residual ECM gel in the liquid state. In addition, for the single-cell method, it is recommended to thoroughly mix the PDOs after trypsin incubation using a normal 1,000 µL tip to break cell clumps before adding the STI, rather than directly filtering the cell suspension with cell strainers, to avoid cell loss.

Some modifications can be made in this protocol. The cell recovery solution can be replaced by ice-cold DPBS for dissolving the ECM gel in the harvesting step. However, experiences showed a better ability to dissolve the ECM gel using the cell recovery solution. Therefore, ice-cold DPBS is rather recommended only as an alternative backup method. If the laboratory is not equipped with a rotating incubator, EAC PDOs can be incubated with trypsin in a 37 °C water bath along with mixing by inverting the tube every 2-3 min. 10% DMSO with fetal bovine serum (FBS) can be used as an alternative for freezing medium to prepare frozen PDO stocks. However, a commercial freezing medium with lower or no serum is preferred due to a better PDO recovery.

Some limitations need to be addressed in this protocol. Since these methods have been tested only in EAC PDOs, the application of this protocol to other types of PDOs is not clear. Although procedures for passaging PDOs with and without single cell digestion are standardized for most organoid types21,22, there is still a need to attempt current protocols on other cancer types to ensure reproducibility. In addition, a 10 min 0.25% trypsin incubation may stress the cells during digestion; therefore, the incubation time could vary based on the pre-subculture PDO condition and the individual PDO diversity. During early attempts, it is suggested to set different trypsin incubation times for each EAC PDO.

In conclusion, this is the first protocol describing and discussing subculture and cryopreservation of EAC PDOs with and without single cell digestion. Subculturing EAC PDOs with single cell digestion is applicable for comparison experiments between groups while undigested EAC PDOs are beneficial for histological characterization, cryopreservation, and quick expansion. Here, the routine maintenance of EAC PDOs is standardized, providing a guide for researchers to choose appropriate methods for EAC organoid generation.

Subscription Required. Please recommend JoVE to your librarian.

Disclosures

The authors declare no conflicts of interest in this work.

Acknowledgments

This work was supported by Köln Fortune Program/Faculty of Medicine, University of Cologne. We thank the technical assistance from Susanne Neiss, Michaela Heitmann, and Anke Wienand-Dorweiler. Ningbo Fan was financially supported by Guangzhou Elite Scholarship Council (GESC). The authors thank Dr. Joshua D'Rozario for his assistance in linguistic editing.

Materials

Name Company Catalog Number Comments
Equipment
-20°C Freezer Bosch Economic
-80°C Freezer Panasonic MDF DU500VH-PE
Automated Cell counter Thermo Fisher AMQAX1000 Countess II
Biological Safety Cabinet Class II Thermo Scientific 51022482 Herasafe KS12
Centrifuge Heraeus 75003060 Megafuge 1.0R
CO2 Incubator Thermo Scientific 50116048 Heracell 150i
Inverted automated fluorescence microscope Olympus IX83
Inverted light microscope Leica DMIL LED Fluo
Pipette 1000 µL Eppendorf 3123000063 Research Plus
Pipette 200 µL Eppendorf 3123000039 Research Plus
Rotating Incubator Scientific Industries, sc. SI-1200 Enviro-genie
Shaker Eppendorf 5355 000.011 Thermomixer Comfort
Vacuum pump Vacuubrand 20727200 BVC control
Waterbath Medingen p2725 W22
Material
15 mL tube Sarstedt 62.554.502 Inc Screw cap tube PP 15 mL
Cryo vial 2 mL Sarstedt 72.379 CryoPure 2.0 mL tube
Low bind tube 1.5 mL Sarstedt 72.706.600 Micro tube 1.5 mL protein LB
Low bind tube 5 mL Eppendorf 0030 108.302 Protein LoBind Tube 5.0 mL
Pipette tip 200 µL Starlab E1011-8000 200 µL Graduated tip, wide orifice
Pipette tip 1000 µL Starlab E1011-9000 1000 µL Graduated tip, wide orifice
Pipette tip 1000 µL Sarstedt 70.3050 Pipette tip 1000 µL
Sterile filter 0.2 µm Sarstedt 83.1826.001 Filtropur 0.2 µm sterile filter
Tissue culture plate Sarstedt 83.3921 12 well-plate
Reagent/Chemical
A83-01 Tocris 2939
Advanced DMEM/F-12 Thermo Fisher Scientific 12634010
Amphotericin B Thermo Fisher Scientific 15290026
B-27 Thermo Fisher Scientific 17504001
Cell Recovery Solution Corning 354253
CHIR-99021 MedChemExpress HY-10182/CS-0181
DNase I grade II, from bovine pancreas Sigma-Aldrich 10104159001
Dulbecco's phosphate-buffered saline (DPBS) Thermo Fisher Scientific 14190094
Extracellular matrix (ECM) gel: Matrigel Growth Factor Reduced (GFR) Basement Membrane Matrix Corning 356231
FGF-10a Peprotech 100-26-100
Freezing medium: Recovery Cell Freezing Medium Thermo Fisher Scientific 12648010
Gastrin Sigma G9020
Gentamicin-25 (25 mg/ 500 µL) PromoCell C-36030
HEPES (1 M) Thermo Fisher Scientific 15630080
L-Glutamine 200 mM (100X) Thermo Fisher Scientific 25030024
N-2 Thermo Fisher Scientific 17502-048
N-Acetylcysteine Sigma A9165
Nicotinamide Sigma N0636-100
Noggin Peprotech 120-10C-50
Penicillin-Streptomycin 10,000 U/ mL (100X) Thermo Fisher Scientific 15140122
Recombinant human epidermal growth factor (EGF) Peprotech AF-100-15
R-Spondin1 conditioned medium from Cultrex R-Spondin Cells Biotechne 3710-001-01
SB202190 MedChemExpress 152121-30-7
Trypsin inhibitor from Glycine max (soybean) Sigma-Aldrich 93620-1G
Trypsin-EDTA (0.25 %), phenol red Thermo Fisher Scientific 25200056
Wnt-3A conditioned medium Wnt-3A expressing cell line was kindly provided by Prof. Hans Clevers' group
Y-27632 Sigma Y0503

DOWNLOAD MATERIALS LIST

References

  1. Sung, H., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 71 (3), 209-249 (2021).
  2. Coleman, H. G., Xie, S. -H., Lagergren, J. The epidemiology of esophageal adenocarcinoma. Gastroenterology. 154 (2), 390-405 (2018).
  3. Rumgay, H., et al. International trends in esophageal squamous cell carcinoma and adenocarcinoma incidence. The American Journal of Gastroenterology. 116 (5), 1072-1076 (2021).
  4. Qian, H., et al. Clinical characteristics, prognosis, and nomogram for esophageal cancer based on adenosquamous carcinoma: a seer database analysis. Frontiers in Oncology. 11, 603349 (2021).
  5. Lagergren, J., Smyth, E., Cunningham, D., Lagergren, P. Oesophageal cancer. Lancet. 390 (10110), London, England. 2383-2396 (2017).
  6. Rockett, J. C., Larkin, K., Darnton, S. J., Morris, A. G., Matthews, H. R. Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. British Journal of Cancer. 75 (2), 258-263 (1997).
  7. Hashimoto, N. Expression of COX2 and p53 in rat esophageal cancer induced by reflux of duodenal contents. ISRN Gastroenterology. 2012, 1-5 (2012).
  8. Quante, M., et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of barrett-like metaplasia. Cancer Cell. 21 (1), 36-51 (2012).
  9. Kapoor, H., Lohani, K. R., Lee, T. H., Agrawal, D. K., Mittal, S. K. Animal models of Barrett's esophagus and esophageal adenocarcinoma-past, present, and future. Clinical and Translational Science. 8 (6), 841-847 (2015).
  10. Lan, T., Xue, X., Dunmall, L. C., Miao, J., Wang, Y. Patient-derived xenograft: a developing tool for screening biomarkers and potential therapeutic targets for human esophageal cancers. Aging. 13 (8), Albany NY. 12273-12293 (2021).
  11. Liu, D. S. H., et al. APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma. Gut. 64 (10), 1506-1516 (2015).
  12. Ebbing, E. A., et al. Esophageal adenocarcinoma cells and xenograft tumors exposed to Erb-b2 receptor tyrosine kinase 2 and 3 inhibitors activate transforming growth factor beta signaling, which induces epithelial to mesenchymal transition. Gastroenterology. 153 (1), 63-76 (2017).
  13. Simian, M., Bissell, M. J. Organoids: A historical perspective of thinking in three dimensions. The Journal of Cell Biology. 216 (1), 31-40 (2017).
  14. Drost, J., Clevers, H. Organoids in cancer research. Nature Reviews Cancer. 18 (7), 407-418 (2018).
  15. Li, X., et al. Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics. Nature Communications. 9, 2983 (2018).
  16. Ebbing, E. A., et al. Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America. 116 (6), 2237-2242 (2019).
  17. Karakasheva, T. A., et al. Generation and characterization of patient-derived head and neck, oral, and esophageal cancer organoids. Current Protocols in Stem Cell Biology. 53 (1), 109 (2020).
  18. Ordóñez, N. G. Broad-spectrum immunohistochemical epithelial markers: a review. Human Pathology. 44 (7), 1195-1215 (2013).
  19. Maniar, K. P., Umpires, B. Cytokeratin 7 (CK7, K7). Pathology Outlines.com website. , https://www.pathologyoutlines.com/topic/stainsck7.html (2021).
  20. Sun, X., Kaufman, P. D. Ki-67: more than a proliferation marker. Chromosoma. 127 (2), 175-186 (2018).
  21. Driehuis, E., Kretzschmar, K., Clevers, H. Establishment of patient-derived cancer organoids for drug-screening applications. Nature Protocols. 15 (10), 3380-3409 (2020).
  22. Sachs, N., et al. Long-term expanding human airway organoids for disease modeling. The EMBO Journal. 38 (4), 100300 (2019).

Tags

Subculture Cryopreservation Esophageal Adenocarcinoma Organoids Single Cell Digestion Protocol Handling Subculture Process Downstream Applications PDO-based Experiments Details Quality Control Team-based SOP PhD Student Laboratory Technique Assistant Incubation ECM Gel Cell Recovery Solution
Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion
Play Video
PDF DOI DOWNLOAD MATERIALS LIST

Cite this Article

Fan, N., Raatz, L., Chon, S. H.,More

Fan, N., Raatz, L., Chon, S. H., Quaas, A., Bruns, C., Zhao, Y. Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion. J. Vis. Exp. (185), e63281, doi:10.3791/63281 (2022).

Less
Copy Citation Download Citation Reprints and Permissions
View Video

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter